ProfileGDS5678 / 1429078_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 88% 87% 88% 89% 91% 90% 87% 88% 89% 89% 90% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1430590
GSM967853U87-EV human glioblastoma xenograft - Control 27.1858990
GSM967854U87-EV human glioblastoma xenograft - Control 36.9539588
GSM967855U87-EV human glioblastoma xenograft - Control 46.7894487
GSM967856U87-EV human glioblastoma xenograft - Control 56.8714788
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7672489
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.18591
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1802690
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5931487
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9079988
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9413689
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0154189
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.2079590
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.8839688